nach oben

Tipp

HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines

verfasst von: MD Elisabeth Foki, MD Isabella Stanisz, MD Lorenz Kadletz, MD Ulana Kotowski, MD, DMD, MSc, MBA Rudolf Seemann, MD Rainer Schmid, MD, PD Gregor Heiduschka

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 1-2/2021

Einloggen, um Zugang zu erhalten

Summary

Background

The selective PI3K (Phosphatidylinositol 3-kinase) inhibitor HS-173 has anticancer activity in non-small cell lung cancer and pancreatic cancer cells. Of all head and neck squamous cell carcinomas (HNSCC) 20% harbor specific mutations in the genome. The aim of this study was to investigate the effect of HS-173 on HNSCC cell lines.

Methods

The cell lines SCC25, CAL27 and FaDu were incubated with HS-173. Its antiproliferative effect was determined using the CCK‑8 cell proliferation assay. Combined incubation with cisplatin was performed and combination index analysis was conducted. To investigate its effect on radiotherapy, cells were irradiated with 2, 4, 6 and 8 Gy, respectively. Synergistic effects of radiation and HS-173 were measured by proliferation assays and clonogenic survival.

Results

The use of HS-173 induced significant reduction of cell proliferation across all cell lines. Most interestingly, it showed a synergistic effect with cisplatin treatment. Clonogenic survival revealed a radiosensitizing effect in CAL27 and FaDu cells. The HS-173 caused significant induction of apoptosis in SCC25 and FaDu cells.

Conclusion

The selective PI3K inhibitor HS-173 is a potent chemosensitizing and also radiosensitizing drug in treatment of HNSCC cell lines and could be an effective treatment in PI3K-mutated HNSCC.

Vorheriger Artikel Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma

Nächster Artikel Molecularly guided treatment of metastatic parotid gland carcinoma in adults

Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008;359:1143–54. CrossRef

Asati V, Mahapatra DK, Bharti SK. PI3K/AKT/mTor and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur J Med Chem. 2016;109(C):314–41. https://doi.org/10.1016/j.ejmech.2016.01.012. CrossRefPubMed

Freudlsperger C, Burnett JR, Friedman JA, Kannabiran VR, Chen Z, Van Waes C. EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets. 2011;15(1):63–74. https://doi.org/10.1517/14728222.2011.541440. CrossRefPubMed

Vermorken JB, Mesia R, Riviera F, et al. Platinum-based chemotherapyplus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27. CrossRef

Bussink J, Kaanders JHAM, van der Kogel AJ. Microenvironmental transformations by VEGF- and EGF-receptor inhibition and potential implications for responsiveness to radiotherapy. Radiother Oncol. 2007;82(1):10–7. https://doi.org/10.1016/j.radonc.2006.10.022. CrossRefPubMed

Perri F, Pacelli R, Scarpati VDG, et al. Radioresistance in head and neck squamous cell carcinoma: biological bases and therapeutic implications. Head Neck. 2015;37(5):763–70. https://doi.org/10.1002/hed.23837. CrossRefPubMed

Seiwert TY, Zuo Z, Keck MK, et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015;21(3):632–41. https://doi.org/10.1158/1078-0432.CCR-13-3310. CrossRefPubMed

Lui VWY, Hedberg ML, Li H, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013;3(7):761–9. https://doi.org/10.1158/2159-8290.CD-13-0103. CrossRefPubMedPubMedCentral

Garlich JR, De P, Dey N, et al. A vascular targeted pan phosphoinositide 3‑Kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008;68(1):206–15. https://doi.org/10.1158/0008-5472.CAN-07-0669. CrossRefPubMed

10.

Michmerhuizen NL, et al. Rationale for using irreversible EGFR-Growth Factor Inhibitors in combination with Phosphatidylinositol3-kinase Inhihitors for advanced head and neck squamous cell carinoma. Mol Pharmacol. 2019;95(5):528–36. CrossRef

11.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7. CrossRef

12.

Kotowski U, Heiduschka G, Seemann R, et al. Wirkung des Kaffeebestandteils Cafestol auf Kopf-Hals-Tumorzelllinien. Strahlenther Onkol. 2015;191(6):511–7. https://doi.org/10.1007/s00066-014-0807-x. CrossRefPubMed

13.

Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1(5):2315–9. https://doi.org/10.1038/nprot.2006.339. CrossRefPubMed

14.

Wicki A, Mandalà M, Massi D, et al. Acquired resistance to clinical cancer therapy: a twist in physiological signaling. Physiol Rev. 2016;96(3):805–29. https://doi.org/10.1152/physrev.00024.2015. CrossRefPubMed

15.

Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27(41):5497–510. https://doi.org/10.1038/onc.2008.245. CrossRefPubMedPubMedCentral

16.

Kean B, Kim S, Ahn Y. In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. Anticancer Res. 2015;35:175–82.

17.

Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer. Mechanisms and advances in clinical trials. Mol Cancer. 2019;28:26. CrossRef

18.

Barrientos JC. Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential. Onco Thargets Ther. 2016;9:2945–53. https://doi.org/10.2147/OTT.S102573. CrossRef

19.

Almasan A, Smith M, Hill B, Madanat Y. Idelalisib therapy of indolent B‑cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas. Blood Lymphat Cancer. 2016;6:1–6. PubMedPubMedCentral

20.

Schötz U, Balzer V, Brandt F. Dual PI3K/mTOR-inhibitor NVP-BEZ235 enhances radiosensitivity in head and neck squamous cell carcinoma (HNSCC) cell lines due to suppressed double-strand break (DSB) repair by non-homologous end joining. Cancers. 2020;12(2):467. CrossRef

21.

Soulières D, Faivre S, Mesia R, et al. Buparlisib and paclitaxel in patients with platinum-Pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a Randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2017;18(3):323–35. CrossRef

22.

Kim SJ, Jung KH, Son MK, et al. Tumor vessel normalization by the PI3K-inhibitor HS-173 enhances drug delivery. Cancer Lett. 2017;403:339–53. CrossRef

23.

Stausbol-Gron B, Overgaard J. Relationship between tumour cell in vitro radiosensitivity and clinical outcome after curative radiotherapy for squamous cell carcinoma of the head and neck. Radiother Oncol. 1999;50:47–55. CrossRef

24.

Baker SJ. PTEN enters the nuclear age. Cell. 2007;128(1):25–8. https://doi.org/10.1016/j.cell.2006.12.02. CrossRefPubMed

25.

Park JH, Jung KH, Kim SH, et al. Radiosensitization of the PI3K-Inhibitor of HS-173 through reduction of DNA damage repair in pancreatic cancer. Oncotarget. 2017;8(68):112893–906. CrossRef

26.

Michmerhuizen NL, Leonard E, Kulkarni A, Brenner JD. Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC. Otorhinolaryngol Head Neck Surg. 2016;1(2):44–50. CrossRef

27.

Niehr F, Eder T, Pilz T, et al. Multilayered omics-based analysis of a head and neck cancer model of cisplatin resistance reveals intratumoral heterogeneity and treatment-induced clonal selection. Clin Cancer Res. 2018;14(1):158–68. CrossRef

Titel: HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines
verfasst von: MD Elisabeth Foki
MD Isabella Stanisz
MD Lorenz Kadletz
MD Ulana Kotowski
MD, DMD, MSc, MBA Rudolf Seemann
MD Rainer Schmid
MD, PD Gregor Heiduschka
Publikationsdatum: 02.09.2020
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 1-2/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-020-01729-3

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines

Summary

Background

Methods

Results

Conclusion

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Summary

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1-2/2021

Serum procalcitonin in Philadelphia-negative myeloproliferative neoplasms

Veranstaltungstipps

Clinical-Pathological Conference Series from the Medical University of Graz

mitteilungen der gesellschaft

Effects of a structured exercise program on physical performance and function, quality of life and work ability of physically active breast cancer survivors

Molecularly guided treatment of metastatic parotid gland carcinoma in adults